Latest & greatest articles for myocardial infarction

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on myocardial infarction or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on myocardial infarction and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for myocardial infarction

161. Assessing and Refining Myocardial Infarction Risk Estimation among Patients with Human Immunodeficiency Virus: Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Full Text available with Trip Pro

Assessing and Refining Myocardial Infarction Risk Estimation among Patients with Human Immunodeficiency Virus: Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Persons with human immunodeficiency virus (HIV) that is treated with antiretroviral therapy have improved longevity but face an elevated risk of myocardial infarction (MI) due to common MI risk factors and HIV-specific factors. Despite these elevated MI rates, optimal methods to predict MI risks for HIV-infected (...) with complete baseline data, 6904 were white and 9250 were men. Myocardial infarction rates were higher among black men (6.9 per 1000 person-years) and black women (7.2 per 1000 person-years) than white men (4.4 per 1000 person-years) and white women (3.3 per 1000 person-years), older participants (7.5 vs 2.2 MI per 1000 person-years for adults 40 years and older vs < 40 years old at study entry, respectively), and participants who were not virally suppressed (6.3 vs 4.7 per 1000 person-years

2017 JAMA cardiology

162. Routine invasive strategies compared with conservative strategies do not lower the all-cause mortality in patients with non-ST elevation myocardial infarction and unstable angina

Routine invasive strategies compared with conservative strategies do not lower the all-cause mortality in patients with non-ST elevation myocardial infarction and unstable angina Routine invasive strategies compared with conservative strategies do not lower the all-cause mortality in patients with non-ST elevation myocardial infarction and unstable angina | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your (...) compared with conservative strategies do not lower the all-cause mortality in patients with non-ST elevation myocardial infarction and unstable angina Article Text Commentary Emergency care Routine invasive strategies compared with conservative strategies do not lower the all-cause mortality in patients with non-ST elevation myocardial infarction and unstable angina Udho Thadani Statistics from Altmetric.com Commentary on: Fanning JP, Nyong J, Scott IA, et al . Routine invasive strategies versus

2017 Evidence-Based Medicine

163. Clinical policy: emergency department management of patients needing reperfusion therapy for acute ST-segment elevation myocardial infarction.

Clinical policy: emergency department management of patients needing reperfusion therapy for acute ST-segment elevation myocardial infarction. Clinical policy: emergency department management of patients needing reperfusion therapy for acute ST-segment elevation myocardial infarction. | National Guideline Clearinghouse success fail May JUN 09 2017 2018 2019 19 May 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive (...) NGC:011295 2017 Nov NEATS Assessment Clinical policy: emergency department management of patients needing reperfusion therapy for acute ST-segment elevation myocardial infarction. Promes SB, Glauser JM, Smith MD, Torbati SS, Brown MD, American College of Emergency Physicians. Clinical policy: emergency department management of patients needing reperfusion therapy for acute ST-segment elevation myocardial infarction. Ann Emerg Med. 2017 Nov;70(5):724-39. [28 references] This is the current release

2017 National Guideline Clearinghouse (partial archive)

164. Beta blockers during acute ST-elevation myocardial infarction (STEMI)

Beta blockers during acute ST-elevation myocardial infarction (STEMI)

2017 DynaMed Plus

169. Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

2017 DynaMed Plus

170. ACE inhibitors during acute ST-elevation myocardial infarction (STEMI)

ACE inhibitors during acute ST-elevation myocardial infarction (STEMI)

2017 DynaMed Plus

172. Intensive Care Unit Utilization Among Medicare Patients Hospitalized with Non-ST-Segment Elevation Myocardial Infarction Full Text available with Trip Pro

Intensive Care Unit Utilization Among Medicare Patients Hospitalized with Non-ST-Segment Elevation Myocardial Infarction Intensive care unit (ICU) utilization may have important implications for the care and outcomes of patients with non-ST-segment elevation myocardial infarction (NSTEMI).To examine interhospital variation in ICU utilization in the United States for older adults with hemodynamically stable NSTEMI and outcomes associated with ICU utilization among patients with low, moderate (...) with ACTION risk scores greater than 40, 30 to 40, and less than 30 (adjusted interaction P = .86).Utilization of the ICU for older patients with NSTEMI varied significantly among hospitals. This variability was not explained by hospital characteristics or driven by patient risk. Mortality after myocardial infarction did not significantly differ among high, intermediate, or low ICU utilization hospitals.

2017 JAMA cardiology

173. 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non?ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures Full Text available with Trip Pro

2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non?ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures | Circulation (...) : Cardiovascular Quality and Outcomes Search Hello Guest! Login to your account Email Password Keep me logged in Search April 2019 March 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart

2017 American Heart Association

174. Brilique (ticagrelor) - myocardial infarction

Brilique (ticagrelor) - myocardial infarction Brilique® (ticagrelor) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Brilique® (ticagrelor) Conclusion The indication for Brilique (ticagrelor), reviewed by IRF in 2011 (1), has been extended to cover also after-treatment of myocardial infarction (MI) beyond 1 year with a lower dose of 60 mg twice daily co-administered with low-dose acetylsalicylic acid (ASA) for up to three years. The approval is based (...) because the risk of re-infarctions is higher in the first year after ACS. It is IRF's overall assessment that extended treatment with Brilique after MI may be considered for high-risk patients who are already treated with Brilique 90 mg twice daily since the majority of adverse reactions and treatment discontinuation due to such occur within the first year of treatment with Brilique (3). The decision to extend treatment should be made by cardiologists already as part of the admission with acute MI. 24

2017 Danish Pharmacotherapy Reviews

175. Cross-sectional study: Increased physical activity in women following myocardial infarction improves health-related quality of life

Cross-sectional study: Increased physical activity in women following myocardial infarction improves health-related quality of life Increased physical activity in women following myocardial infarction improves health-related quality of life | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Increased physical activity in women following myocardial infarction improves health-related quality of life Article Text Adult nursing Cross-sectional

2017 Evidence-Based Nursing

176. Early invasive strategy should be performed within 72 hours in high-risk patients with non-ST-elevation myocardial infarction

Early invasive strategy should be performed within 72 hours in high-risk patients with non-ST-elevation myocardial infarction Early invasive strategy should be performed within 72 hours in high-risk patients with non-ST-elevation myocardial infarction | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Early invasive strategy should be performed within 72 hours in high-risk patients with non-ST-elevation myocardial infarction Article Text

2017 Evidence-Based Medicine

177. Acute myocardial infarction can be ruled out with a single high-sensitivity cardiac troponin T level

Acute myocardial infarction can be ruled out with a single high-sensitivity cardiac troponin T level Acute myocardial infarction can be ruled out with a single high-sensitivity cardiac troponin T level | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Acute myocardial infarction can be ruled out with a single high-sensitivity cardiac troponin T level Article Text Commentary: Emergency care Acute myocardial infarction can be ruled out

2017 Evidence-Based Medicine

178. Stent choice in cardiogenic shock complicating acute myocardial infarction likely does not affect mortality or reinfarction

Stent choice in cardiogenic shock complicating acute myocardial infarction likely does not affect mortality or reinfarction Stent choice in cardiogenic shock complicating acute myocardial infarction likely does not affect mortality or reinfarction | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Stent choice in cardiogenic shock complicating acute myocardial infarction likely does not affect mortality or reinfarction Article Text

2017 Evidence-Based Medicine

179. Ticagrelor for preventing atherothrombotic events after myocardial infarction

Ticagrelor for preventing atherothrombotic events after myocardial infarction Ticagrelor for pre Ticagrelor for prev venting enting atherothrombotic e atherothrombotic ev vents after ents after m my yocardial infarction ocardial infarction T echnology appraisal guidance Published: 14 December 2016 nice.org.uk/guidance/ta420 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

180. Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. Full Text available with Trip Pro

Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. Inflammation of the arterial wall plays a central role in the pathogenesis of atherosclerosis. Among patients with rheumatic diseases, anti-rheumatic medication reduces the incidence of cardiovascular (CV) diseases, but only few studies have addressed their cardioprotective effects on patients with no rheumatic diseases. Hydroxychloroquine (HCQ (...) ) is an anti-rheumatic drug commonly used in the treatment of rheumatoid arthritis and systemic lupus erythematosus. In addition to its anti-inflammatory properties, HCQ reduces cholesterol levels and the risk of type II diabetes, and has also anti-platelet effects.The OXI trial is an event-driven trial that will randomize 2500 patients hospitalized for myocardial infarction (MI). Participants will receive active HCQ or placebo for at least 12 months, and until 350 CV events are confirmed. The primary

2016 European heart journal. Cardiovascular pharmacotherapy Controlled trial quality: uncertain